LSI USA '23 filling fast. Register Now

Mnemosyne Pharmaceuticals

First-in-class subunit-selective NMDA receptor modulators to treat neuropsychiatric diseases, specifically schizophrenia and Alzheimer\'s

Start Trial Get Full Profile

There’s no risk. Start your trial today to see profiles of Mnemosyne Pharmaceuticals plus 5408 other startups.

Start Free 7 Day Trial Now

Learn More About Mnemosyne Pharmaceuticals

Technology/product details

Revenue projections

Capital raised to date

Growth strategy

Competing Startups

More

Our Clients